'Total Worldwide Revenues from Drugs to Treat Eye Disorders Will Reach $23.8bn in 2016' Predicts New Visiongain's Report

LONDON, October 18, 2012 /PRNewswire/ --

A new report by Visiongain predicts that total worldwide revenues from drugs to treat eye disorders will reach $23.8bn in 2016. Leading companies will achieve high sales growth from 2012 to 2022. That sales prediction and other forecasts appear in Pharma Leader Series: Top 20 Ophthalmic Drug Manufacturers 2012-2022, published in October 2012. Visiongain is a business information provider based in London, UK.

The world market for ophthalmic drugs is a profitable segment of the healthcare market. The market for medicines to treat eye diseases is dominated by large pharma companies, which occupy five of the ten leading ophthalmic manufacturers' positions. The others participants are specialist companies, with three focused entirely on ophthalmic pharmaceutical products. In 2011, the top 10 ophthalmic drug manufacturers accounted for 70.6% of overall world revenues in this sector. US-based manufacturers dominate the ophthalmic drug industry and market, with a new entrant, Regeneron - with its recent launch of Eylea (for wet AMD) - rapidly establishing itself in that market.

The overall ophthalmic medicines market is stimulated by a rising prevalence of eye disorders worldwide. The main causes of visual impairment and loss in the developed countries are retinal diseases, such as age-related macular degeneration (AMD), diabetic macular (o)edema, and macular (o)edema due to retinal vein occlusion. Worldwide, over 50 million patients are estimated to have AMD, with prevalence rates expected to double by 2020. Glaucoma, the leading cause of irreversible blindness, affects an estimated 70 million people worldwide. Its treatment remains one of the largest segments of the ophthalmic prescription drugs market.

Dr Syed Ahmed, a senior pharma industry analyst in visiongain, said: "The top 20 ophthalmic drug manufacturers are a mix of large cap and mid cap specialist companies. Many of those companies have a long history in the industry, with some having been among the first organisations to launch eye care products. Nevertheless, several leading firms will see their places challenged over the next 10 years. Our strong revenue growth forecast for the ophthalmic drug market shows it to be an attractive proposition from 2012 to 2022, and many new entrants seek to enter that market. Clearly, too, its R&D pipeline is strong and promising.

"Visiongain believes future success for ophthalmic drug manufacturers will depend on launches of new compounds, particularly neuroprotective anti-glaucoma drugs and new delivery systems and formulations, including greater use of sustained-release implant and injection technologies for retinal diseases."

This decade many opportunities for treating eye diseases will occur, with new medicines launched. There are many opportunities for novel drugs. Pharma corporations and specialty healthcare operations will develop and prosper, visiongain's analyses show.

Pharma Leader Series: Top 20 Ophthalmic Drug Manufacturers 2012-2022 adds to visiongain's range of analytical reports on industries and markets in healthcare.

For further information concerning the Visiongain's Pharma Leader Series: Top 20 Ophthalmic Drug Manufacturers 2012-2022 report please visit http://www.visiongain.com/Report/911/Pharma-Leader-Series-Top-20-Ophthalmic-Drug-Manufacturers-2012-2022

For an executive summary please contact: Sara Peerun sara.peerun@visiongainglobal.com or Tel: +44 (0) 20 7336

Companies Listed

Alcon Laboratories
Alimera Sciences
Allergan
Allergan Pharmaceuticals Ireland
American Academy of Ophthalmology (AAO)
American Diabetes Association
American Society of Retina Specialists (ASRS)
AmpliPhi BioSciences Corporation
Asahi
Astellas Pharma
AstraZeneca
Banyu Pharmaceutical Co (currently MSD K.K.)
Bausch + Lomb (B&L)
Bayer
Bayer HealthCare
Bayer Yakuhin (Bayer's Japanese subsidiary)
Bristol-Myers Squibb
BioDiem
BioInvent International
Cambridge University
Centre for Molecular and Vascular Biology, KU Leuven.
Chugai
CIBA Vision
Ciba-Geigy
Clinical Data
CoMentis
CT Freda
Daiichi Sankyo
EAME countries
Eli Lilly
Esteve
European Medicines Agency (EMEA/EMA)
EyeTech Pharmaceuticals (now OSI Pharmaceuticals)
Food and Drug Administration (FDA) [US]
Forest Laboratories
Gene Signal
Genentech
GenVec
Gilead Sciences,
GlaxoSmithKline (GSK)
Harvard Business School
Hoffman La Roche
Inspire Pharmaceuticals
ISTA Pharmaceuticals
Johns Hopkins University
KAI Pharmaceuticals
Kyorin Pharmaceutical
Kyowa Hakko Kirin
LEO Pharma
Lpath
MacuSight
Meda
Merck & Co.
Merial
MerLion Pharmaceuticals
Ministry for Health, Labor and Welfare [Japan]
Molecular Partners
Monash University
MSD K.K
Mylan Seiyaku
National Eye Institute (NEI)
National Health Service (NHS)
National Institute for Health and Clinical Excellence (NICE)
Neurotech
Nichi-Iko Pharmaceutical
Nipro Pharma
Nobilon International
NovaBay Pharmaceuticals
Novagali Pharma
Novartis
Novartis Institutes for BioMedical Research (NIBR)
Oklahoma Medical Research Foundation
Ophthotech
OPKO Health
OSI Pharmaceuticals
Othera Pharmaceuticals
Oxford BioMedica
Oxigene
Pfizer
Pharmacia
Potentia
pSivida
Purdue University
QLT
Quark
Regeneron
ReVision Therapeutics
Roche
Sandoz
Sanofi
Santen Pharmaceutical Co.
Senju Pharmaceuticals Science & Technology (Beijing) Co.
Senju Pharmaceutical
Senju USA
Shandong University
Shire
Sirion Therapeutics
Sirnaomics
Sun Pharmaceutical Industries
Taiyo Yakuhin
Takeda
TargeGen
Teva Pharmaceutical Industries
Therapeutic Goods Administration (TGA)
ThromboGenics
University College London
University of Melbourne
Upjohn
Warburg Pincus
Warner-Lambert
Watson Pharmaceuticals
Wyeth Pharmaceuticals 

About visiongain
Visiongain is one of the fastest growing and most innovative independent media companies in Europe. Based in London, UK, visiongain produces a host of business-2-business conferences, newsletters, management reports and e-zines focusing on the Energy, Telecoms, Pharmaceutical, Defence, Materials sectors.

Visiongain publishes reports produced by its in-house analysts, who are qualified experts in their field. Visiongain has firmly established itself as the first port-of-call for the business professional, who needs independent, high quality, original material to rely and depend on.

Notes for Editors
If you are interested in a more detailed overview of this report, please send an e-mail to sara.peerun@visiongainglobal.com or call her on +44(0)207-336-6100.